Purchase Order W81K0024P0073
Award Date 5/1/24
Potential Completion Date 4/30/27
Potential Value $22K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Fort Bliss, TX 79916, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a for-profit manufacturer of the INTERCEPT Blood System, a pathogen reduction technology for platelets and plasma. The $369,384 contract is for the supply of INTERCEPT Platelet Processing Sets, Dual Storage Containers, and maintenance services for INTERCEPT Blood System illuminators to support medical readiness and blood product safety at military healthcare facilities. The contract has...
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety. Cerus has a history of supplying its...
- The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
- The Defense Health Agency awarded a $104,256 firm fixed-price purchase order to Cerus Corporation on September 30, 2019, for INTERCEPT Platelet Small Volume Sets, with performance through September 3, 2024. The contract was awarded without a set-aside designation to Cerus Corporation, a Concord, California-based biomedical products manufacturer specializing in blood safety technologies. Cerus's INTERCEPT Blood System uses riboflavin and ultraviolet light technology to inactivate pathogens in...
- This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that manufactures the INTERCEPT Blood System technology for pathogen reduction in blood components. The contract is for the DROP SHIPMENT OF INTERCEPT DUAL, with a potential value of $66,624.00 and a completion date of January 1, 2024. Cerus Corporation, the prime contractor, is a for-profit manufacturer that has received over 20 federal contract awards from...
- This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $14,924.64, is for the provision of INTERCEPT Blood System equipment, illuminator maintenance services, and specialized pathogen reduction technology products. The contract has a performance period ending on June 7, 2025. Cerus...
- The Defense Health Agency issued a purchase order to Cerus Corporation for CERUS INTERCEPT Platelet Processing Sets on October 1, 2025, with a ceiling value of $367,100. Performance is located in Concord, California, and the order extends through September 30, 2030. The procurement, structured as firm fixed-price, originated from a sources sought notice posted by Tripler Army Medical Center in June 2025 to assess market capabilities for specialized blood processing equipment. The INTERCEPT Blood...
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract is for the delivery of INTERCEPT Platelet Processing Sets, which are used to inactivate pathogens in blood platelets. The contract has a ceiling value of $295,760.00 and an ultimate completion date of January 31, 2022. Cerus Corporation has consistently secured sole-source...
- This is a firm-fixed price purchase order awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency within the Department of Veterans Affairs, to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The $82,389 contract is for the supply of INTERCEPT Illuminator 60 Hz systems and associated maintenance services. The illuminators are essential components of Cerus Corporation's proprietary INTERCEPT Blood System,...
- The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...